RxDoctor Payments Data

Edward Julie, MD

Cardiovascular Disease · Clifton, NJNPI 1497701163

Payments from drug & device makers

$20,036in general payments, 2019–2025

Across 203 payments — averaging $98.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$17K
  • Amgen$611
  • Novartis$543
  • Merck$240
  • Edwards Lifesciences$197
  • Pfizer$192
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$15,50077%
  • Travel & lodging$6843%
  • Food & beverage$3,85219%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,036 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$370,027
Medicare patients
1,043
Services billed
4,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban456$508,071
VyndamaxTafamidis13$336,562
EntrestoSacubitril/Valsartan229$242,782
XareltoRivaroxaban103$111,634
Repatha SureclickEvolocumab54$70,592
Nebivolol Hcl671$41,160
Praluent PenAlirocumab37$40,011
NexlizetBempedoic Acid/Ezetimibe24$18,695
LivaloPitavastatin Calcium36$18,090
MultaqDronedarone Hcl22$17,426
Metoprolol Succinate1,026$16,526
DiovanValsartan11$16,406
Rosuvastatin Calcium1,052$15,980
VascepaIcosapent Ethyl23$15,302
BystolicNebivolol Hcl28$14,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$192$844,633469 claims
NovartisEntresto, Diovan$543$259,188240 claims
Johnson & JohnsonXarelto$16,699$111,634103 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$153$32,95264 claims
Esperion Therapeutics, Inc.Nexlizet$98$18,69524 claims
Sanofi-aventis U.S. LLCMultaq$116$17,42622 claims
AstraZenecaFarxiga, Atacand$40$16,99125 claims
MerckVerquvo$240$13,61813 claims
Boehringer IngelheimJardiance$107$12,38818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →